The central role of extracellular vesicles in the mechanisms of thrombosis in paroxysmal nocturnal haemoglobinuria: a review

References

• Dameshek W, Fudenberg H. Paroxysmal nocturnal hemoglobinuria. AMA Arch Intern Med. 1957; 99: 202–8.
   Google Scholar
• Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A et al. Evidence for circulating bone marrow-derived endothelial cells. Blood. 1998; 92: 362–7.
   PubMed Web of Science ®Google Scholar
• Parker CJ. Management of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitory therapy. Hematology Am Soc Hematol Educ Program. 2011; 2011: 21–9.
   PubMed Web of Science ®Google Scholar
• Weitz IC. Thrombosis in patients with paroxysmal nocturnal hemoglobinuria. Semin Thromb Hemost. 2011; 37: 315–21.
   Web of Science ®Google Scholar
• Schubert J, Hillmen P, Roth A, Young NS, Elebute MO, Szer J et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2008; 142: 263–72.
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008; 111: 1840–7.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Elebute M, Kelly R, Urbano-Ispizua A, Hill A, Rother RP et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2010; 85: 553–9.
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011; 117: 6786–92.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Muus P, Duhrsen U, Risitano AM, Schubert J, Luzzatto L et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007; 110: 4123–8.
   PubMed Web of Science ®Google Scholar
• Weitz IC, Razavi P, Rochanda L, Zwicker J, Furie B, Manly D et al. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation. Thromb Res. 2012; 130: 361–8.
   PubMed Web of Science ®Google Scholar
• Helley D, de Latour RP, Porcher R, Rodrigues CA, Galy-Fauroux I, Matheron J et al. Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Haematologica. 2010; 95: 574–81.
   PubMed Web of Science ®Google Scholar
• Malato A, Saccullo G, Coco LL, Mancuso S, Santoro M, Martino S et al. Thrombotic complications in paroxysmal nocturnal haemoglobinuria: a literature review. Blood Transfus. 2012; 10: 428–35.
   PubMed Web of Science ®Google Scholar
• Ziakas PD, Poulou LS, Rokas GI, Bartzoudis D, Voulgarelis M. Thrombosis in paroxysmal nocturnal hemoglobinuria: sites, risks, outcome. An overview. J Thromb Haemost. 2007; 5: 642–5.
   Web of Science ®Google Scholar
• Araten DJ, Thaler HT, Luzzatto L. High incidence of thrombosis in African-American and Latin-American patients with Paroxysmal Nocturnal Haemoglobinuria. Thromb Haemost. 2005; 93: 88–91.
   Web of Science ®Google Scholar
• de Latour RP, Mary JY, Salanoubat C, Terriou L, Etienne G, Mohty M et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood. 2008; 112: 3099–106.
   PubMed Web of Science ®Google Scholar
• Audebert HJ, Planck J, Eisenburg M, Schrezenmeier H, Haberl R. Cerebral ischemic infarction in paroxysmal nocturnal hemoglobinuria report of 2 cases and updated review of 7 previously published patients. J Neurol. 2005; 252: 1379–86.
   Web of Science ®Google Scholar
• Gyorgy B, Szabo TG, Pasztoi M, Pal Z, Misjak P, Aradi B et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci. 2011; 68: 2667–88.
   PubMed Web of Science ®Google Scholar
• Lacroix R, Dubois C, Leroyer AS, Sabatier F, Dignat-George F. Revisited role of microparticles in arterial and venous thrombosis. J Thromb Haemost. 2013; 11: 24–35.
   PubMed Web of Science ®Google Scholar
• Morel O, Jesel L, Freyssinet JM, Toti F. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol. 2011; 31: 15–26.
   PubMed Web of Science ®Google Scholar
• Sinauridze EI, Kireev DA, Popenko NY, Pichugin AV, Panteleev MA, Krymskaya OV et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost. 2007; 97: 425–34.
   PubMed Web of Science ®Google Scholar
• Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost. 2009; 101: 439–51.
   PubMed Web of Science ®Google Scholar
• Piccin A, Murphy WG, Smith OP. Circulating microparticles: pathophysiology and clinical implications. Blood Rev. 2007; 21: 157–71.
   PubMed Web of Science ®Google Scholar
• Bevers EM, Wiedmer T, Comfurius P, Shattil SJ, Weiss HJ, Zwaal RF et al. Defective Ca(2+)-induced microvesiculation and deficient expression of procoagulant activity in erythrocytes from a patient with a bleeding disorder: a study of the red blood cells of Scott syndrome. Blood. 1992; 79: 380–8.
   PubMed Web of Science ®Google Scholar
• Owens AP 3rd, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res. 2011; 108: 1284–97.
   PubMed Web of Science ®Google Scholar
• Bidot L, Jy W, Bidot C Jr, Jimenez JJ, Fontana V, Horstman LL et al. Microparticle-mediated thrombin generation assay: increased activity in patients with recurrent thrombosis. J Thromb Haemost. 2008; 6: 913–9.
   PubMed Web of Science ®Google Scholar
• Osterud B. Tissue factor expression in blood cells. Thromb Res. 2010; 125: S31–4.
   PubMed Web of Science ®Google Scholar
• Del Conde I, Shrimpton CN, Thiagarajan P, Lopez JA. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood. 2005; 106: 1604–11.
   PubMed Web of Science ®Google Scholar
• Owens AP 3rd, Mackman N. Role of tissue factor in atherothrombosis. Curr Atheroscler Rep. 2012; 14: 394–401.
   PubMed Web of Science ®Google Scholar
• Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood. 2013; 122: 1873–80.
   PubMed Web of Science ®Google Scholar
• Langer F, Ruf W. Synergies of phosphatidylserine and protein disulfide isomerase in tissue factor activation. Thromb Haemost. 2014; 111(3): [Epub ahead of print].
   Google Scholar
• Collier ME, Mah PM, Xiao Y, Maraveyas A, Ettelaie C. Microparticle-associated tissue factor is recycled by endothelial cells resulting in enhanced surface tissue factor activity. Thromb Haemost. 2013; 110: 966–76.
   PubMed Web of Science ®Google Scholar
• Davila M, Robles-Carrillo L, Unruh D, Huo Q, Gardiner C, Sargent IL et al. Microparticle association and heterogeneity of tumor-derived tissue factor in plasma: is it important for coagulation activation?. J Thromb Haemost. 2014; 12: 186–96.
   PubMed Web of Science ®Google Scholar
• Gheldof D, Hardij J, Cecchet F, Chatelain B, Dogne JM, Mullier F. Thrombin generation assay and transmission electron microscopy: a useful combination to study tissue factor-bearing microvesicles. J Extracell Vesicles. 2013; 2 19728, doi: http://dx.doi.org/10.3402/jev.v2i0.19728.
   Google Scholar
• Hugel B, Socie G, Vu T, Toti F, Gluckman E, Freyssinet JM et al. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood. 1999; 93: 3451–6.
   PubMed Web of Science ®Google Scholar
• Liebman HA, Feinstein DI. Thrombosis in patients with paroxysmal noctural hemoglobinuria is associated with markedly elevated plasma levels of leukocyte-derived tissue factor. Thromb Res. 2003; 111: 235–8.
   Web of Science ®Google Scholar
• Van Bijnen ST, Van Heerde WL, Muus P. Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria. J Thromb Haemost. 2012; 10: 1–10.
   Web of Science ®Google Scholar
• Mullier F, Minet V, Bailly N, Devalet B, Douxfils J, Chatelain C et al. Platelet microparticle generation assay: a valuable test for immune heparin-induced thrombocytopenia diagnosis. Thromb Res. 2013. [Epub ahead of print].
   Web of Science ®Google Scholar
• Gurney D, Lip GY, Blann AD. A reliable plasma marker of platelet activation: does it exist?. Am J Hematol. 2002; 70: 139–44.
   PubMed Web of Science ®Google Scholar
• Yahata T, Suzuki C, Yoshioka A, Hamaoka A, Ikeda K. Platelet activation dynamics evaluated using platelet-derived microparticles in Kawasaki disease. Circ J. 2013; 78: 188–93.
   Web of Science ®Google Scholar
• Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2003; 102: 3587–91.
   PubMed Web of Science ®Google Scholar
• Poskitt TR, Fortwengler HP Jr, Lunskis BJ. Activation of the alternate complement pathway by autologous red cell stroma. J Exp Med. 1973; 138: 715–22.
   PubMed Web of Science ®Google Scholar
• Kozuma Y, Sawahata Y, Takei Y, Chiba S, Ninomiya H. Procoagulant properties of microparticles released from red blood cells in paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2011; 152: 631–9.
   Web of Science ®Google Scholar
• Simak J, Holada K, Risitano AM, Zivny JH, Young NS, Vostal JG. Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2004; 125: 804–13.
   PubMed Web of Science ®Google Scholar
• Schaer DJ, Buehler PW. Cell-free hemoglobin and its scavenger proteins: new disease models leading the way to targeted therapies. Cold Spring Harb Perspect Med. 2013; 3: a013433.
   Web of Science ®Google Scholar
• Ritis K, Doumas M, Mastellos D, Micheli A, Giaglis S, Magotti P et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol. 2006; 177: 4794–802.
   PubMed Web of Science ®Google Scholar
• Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med. 2006; 12: 682–7.
   PubMed Web of Science ®Google Scholar
• Steppich B, Mattisek C, Sobczyk D, Kastrati A, Schomig A, Ott I. Tissue factor pathway inhibitor on circulating microparticles in acute myocardial infarction. Thromb Haemost. 2005; 93: 35–9.
   PubMed Web of Science ®Google Scholar
• Jankowska AM, Szpurka H, Calabro M, Mohan S, Schade AE, Clemente M et al. Loss of expression of neutrophil proteinase-3: a factor contributing to thrombotic risk in paroxysmal nocturnal hemoglobinuria. Haematologica. 2011; 96: 954–62.
   Web of Science ®Google Scholar
• Dragoni F, Iori AP, Pignoloni P, Minotti C, Chiarotti F, Mazzucconi MG et al. Thrombophilic screening in patients with paroxysmal nocturnal haemoglobinuria: a pilot study. Br J Haematol. 2010; 150: 492–4.
   PubMed Web of Science ®Google Scholar
• Grünewald M, Siegemund A, Grünewald A, Schmid A, Koksch M, Schopflin C et al. Plasmatic coagulation and fibrinolytic system alterations in PNH: relation to clone size. Blood Coagul Fibrinolysis. 2003; 14: 685–95.
   PubMed Web of Science ®Google Scholar
• Plesner T, Behrendt N, Ploug M. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells. 1997; 15: 398–408.
   PubMed Web of Science ®Google Scholar
• Sloand EM, Pfannes L, Scheinberg P, More K, Wu CO, Horne M et al. Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients. Exp Hematol. 2008; 36: 1616–24.
   Web of Science ®Google Scholar
• Ploug M, Eriksen J, Plesner T, Hansen NE, Dano K. A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria. Eur J Biochem. 1992; 208: 397–404.
   Google Scholar
• Ginestra A, Monea S, Seghezzi G, Dolo V, Nagase H, Mignatti P et al. Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J Biol Chem. 1997; 272: 17216–22.
   PubMed Web of Science ®Google Scholar
• Ginestra A, Miceli D, Dolo V, Romano FM, Vittorelli ML. Membrane vesicles in ovarian cancer fluids: a new potential marker. Anticancer Res. 1999; 19: 3439–45.
   Web of Science ®Google Scholar
• Angelucci A, D'Ascenzo S, Festuccia C, Gravina GL, Bologna M, Dolo V et al. Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines. Clin Exp Metastasis. 2000; 18: 163–70.
   PubMed Web of Science ®Google Scholar
• Lacroix R, Sabatier F, Mialhe A, Basire A, Pannell R, Borghi H et al. Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro. Blood. 2007; 110: 2432–9.
   PubMed Web of Science ®Google Scholar
• Kwaan HC, Rego EM. Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia. Semin Thromb Hemost. 2010; 36: 917–24.
   PubMed Web of Science ®Google Scholar
• Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004; 292: 1555–62.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med. 2008; 168: 2377–81.
   PubMed Web of Science ®Google Scholar
• Abu-Rustum NR, Richard S, Wilton A, Lev G, Sonoda Y, Hensley ML et al. Transfusion utilization during adnexal or peritoneal cancer surgery: effects on symptomatic venous thromboembolism and survival. Gynecol Oncol. 2005; 99: 320–6.
   Web of Science ®Google Scholar
• Nilsson KR, Berenholtz SM, Garrett-Mayer E, Dorman T, Klag MJ, Pronovost PJ. Association between venous thromboembolism and perioperative allogeneic transfusion. Arch Surg. 2007; 142: 126–32. discussion 33.
   PubMed Web of Science ®Google Scholar
• Tan TW, Farber A, Hamburg NM, Eberhardt RT, Rybin D, Doros G et al. Blood transfusion for lower extremity bypass is associated with increased wound infection and graft thrombosis. J Am Coll Surg. 2013; 216: 1005–14. e2;quiz 31–3.
   Web of Science ®Google Scholar
• Kumar MA, Boland TA, Baiou M, Moussouttas M, Herman JH, Bell RD et al. Red blood cell transfusion increases the risk of thrombotic events in patients with subarachnoid hemorrhage. Neurocrit Care. 2014; 20: 84–90.
   Web of Science ®Google Scholar
• Rubin O, Delobel J, Prudent M, Lion N, Kohl K, Tucker EI et al. Red blood cell-derived microparticles isolated from blood units initiate and propagate thrombin generation. Transfusion. 2013; 53: 1744–54.
   PubMed Web of Science ®Google Scholar
• Spinella PC, Carroll CL, Staff I, Gross R, Mc Quay J, Keibel L et al. Duration of red blood cell storage is associated with increased incidence of deep vein thrombosis and in hospital mortality in patients with traumatic injuries. Crit Care. 2009; 13(R151):
   Google Scholar
• Moyo VM, Mukhina GL, Garrett ES, Brodsky RA. Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. Br J Haematol. 2004; 126: 133–8.
   PubMed Web of Science ®Google Scholar
• Robert S, Lacroix R, Poncelet P, Harhouri K, Bouriche T, Judicone C et al. High-sensitivity flow cytometry provides access to standardized measurement of small-size microparticles--brief report. Arterioscler Thromb Vasc Biol. 2012; 32: 1054–8.
   PubMed Web of Science ®Google Scholar
• Lacroix R, Judicone C, Poncelet P, Robert S, Arnaud L, Sampol J et al. Impact of pre-analytical parameters on the measurement of circulating microparticles: towards standardization of protocol. J Thromb Haemost. 2012; 10: 437–46.
   PubMed Web of Science ®Google Scholar
• Lacroix R, Robert S, Poncelet P, Kasthuri RS, Key NS, Dignat-George F et al. Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost. 2010; 8: 2571–4.
   PubMed Web of Science ®Google Scholar
• Mullier F, Bailly N, Chatelain C, Chatelain B, Dogne JM. Pre-analytical issues in the measurement of circulating microparticles: current recommendations and pending questions. J Thromb Haemost. 2013; 11: 693–6.
   PubMed Web of Science ®Google Scholar